ABCG2 Gene Expression in Non-Small Cell Lung Cancer DOI Creative Commons
Agnieszka Jeleń, Marta Żebrowska, Mariusz Łochowski

и другие.

Biomedicines, Год журнала: 2024, Номер 12(10), С. 2394 - 2394

Опубликована: Окт. 19, 2024

Background/Objectives: ATP-binding cassette subfamily G member 2 [ABCG2/breast cancer resistance protein (BCRP)] contributes to mechanisms of multidrug (MDR) and is a marker side population (SP) cells in human cancers. The primary objective this study was investigate the impact ABCG2 gene expression on non-small cell lung (NSCLC) development, course disease, patient prognosis using publicly available data. Obtained results were supplemented with assessment blood NSCLC patients. Methods: dataset analyzed utilizing TIMER 2.0, UALCAN, TNMplot, MEXPRESS, cBioPortal, MethSurv, KM Plotter, STRING, ShinyGO 0.80 databases. Blood samples from 50 patients assessed real-time PCR method. Results: expressed at low level NSCLC, did not correlate clinical aggressiveness cancer. Higher improved overall survival, but only LUAD. In addition, CpG sites located island affecting patient’s indicated. case our own laboratory results, reveal any changes levels collected different time points during diagnostic–therapeutic procedure. silico analysis, most interactors associated development drug resistance. Conclusions: appears have particularly significant survival effect immunotherapy related immune infiltration. Presented findings may support personalized medicine strategies based bioinformatics findings.

Язык: Английский

Artificial intelligence in tumor drug resistance: Mechanisms and treatment prospects DOI
Jianyou Gu, Junfeng Zhang,

Silüe Zeng

и другие.

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0

PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor DOI
Siyuan Wang, Yu Xia, Yiyu Qian

и другие.

Drug Resistance Updates, Год журнала: 2025, Номер unknown, С. 101247 - 101247

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: in vitro and in vivo studies DOI
Xing-Duo Dong, Meng Zhang,

Qiu‐Xu Teng

и другие.

Cancer Letters, Год журнала: 2024, Номер unknown, С. 217309 - 217309

Опубликована: Окт. 1, 2024

Язык: Английский

Процитировано

3

Multidrug resistance transporters P-gp and BCRP limit the efficacy of ATR inhibitor ceralasertib in cancer cells DOI Creative Commons
Xuan-Yu Chen,

Zhuo‐Xun Wu,

Jing‐Quan Wang

и другие.

Frontiers in Pharmacology, Год журнала: 2024, Номер 15

Опубликована: Май 2, 2024

The therapeutic effect of chemotherapy and targeted therapy are known to be limited by drug resistance. Substantial evidence has shown that ATP-binding cassette (ABC) transporters P-gp BCRP significant contributors multidrug resistance (MDR) in cancer cells. In this study, we demonstrated a clinical-staged ATR inhibitor ceralasertib is susceptible BCRP-mediated MDR. resistant cells were less sensitive compared the parental Moreover, can reversed inhibiting efflux activity BCRP. Interestingly, was able downregulate level but not BCRP, suggesting potential regulation between signaling expression. Furthermore, computational docking analysis predicted high affinities drug-binding sites summary, overexpression sufficient confer ceralasertib, underscoring their role as biomarkers for efficacy.

Язык: Английский

Процитировано

2

CYP1B1 Promotes PARPi-Resistance via Histone H1.4 Interaction and Increased Chromatin Accessibility in Ovarian Cancer DOI Creative Commons
Yite Xue,

Taotao Yin,

Shuo Yuan

и другие.

Drug Resistance Updates, Год журнала: 2024, Номер 77, С. 101151 - 101151

Опубликована: Сен. 12, 2024

Язык: Английский

Процитировано

2

Role of solute carrier transporters in ovarian cancer (Review) DOI Creative Commons
Barbara Quaresima, Stefania Scicchitano, Maria Concetta Faniello

и другие.

International Journal of Molecular Medicine, Год журнала: 2024, Номер 55(2)

Опубликована: Ноя. 27, 2024

Solute carrier (SLC) transporters are involved in various biological processes associated with metabolic reprogramming and cancer, supporting the increased requirement of nutrients energy. Over past decade, there have been significant advancements understanding expression function SLCs ovarian cancer (OC). This gynecological condition has a high mortality rate limited treatment options; thus, early diagnosis remains target clinically. OC exhibits complexity heterogeneity, resulting different clinical characteristics, resistance to chemotherapy drugs poor prognosis. Additionally, pattern between healthy tumor tissue, consequently, their inhibition or activation could modify signaling pathways growth process, such as cell proliferation, apoptosis drug accumulation. The present review aims consolidate current data provide comprehensive potential importance OC. it seeks offer guidance for further research on utilizing prognostic biomarkers therapeutic targets.

Язык: Английский

Процитировано

1

Editorial: ABC transporters and drug resistance DOI

Qisi Lu,

Suresh V. Ambudkar, Dong‐Hua Yang

и другие.

Drug Resistance Updates, Год журнала: 2024, Номер 77, С. 101135 - 101135

Опубликована: Авг. 10, 2024

Язык: Английский

Процитировано

0

ABCG2 Gene Expression in Non-Small Cell Lung Cancer DOI Creative Commons
Agnieszka Jeleń, Marta Żebrowska, Mariusz Łochowski

и другие.

Biomedicines, Год журнала: 2024, Номер 12(10), С. 2394 - 2394

Опубликована: Окт. 19, 2024

Background/Objectives: ATP-binding cassette subfamily G member 2 [ABCG2/breast cancer resistance protein (BCRP)] contributes to mechanisms of multidrug (MDR) and is a marker side population (SP) cells in human cancers. The primary objective this study was investigate the impact ABCG2 gene expression on non-small cell lung (NSCLC) development, course disease, patient prognosis using publicly available data. Obtained results were supplemented with assessment blood NSCLC patients. Methods: dataset analyzed utilizing TIMER 2.0, UALCAN, TNMplot, MEXPRESS, cBioPortal, MethSurv, KM Plotter, STRING, ShinyGO 0.80 databases. Blood samples from 50 patients assessed real-time PCR method. Results: expressed at low level NSCLC, did not correlate clinical aggressiveness cancer. Higher improved overall survival, but only LUAD. In addition, CpG sites located island affecting patient’s indicated. case our own laboratory results, reveal any changes levels collected different time points during diagnostic–therapeutic procedure. silico analysis, most interactors associated development drug resistance. Conclusions: appears have particularly significant survival effect immunotherapy related immune infiltration. Presented findings may support personalized medicine strategies based bioinformatics findings.

Язык: Английский

Процитировано

0